Previous Study: TRIO-CIRG 011
Next Study: TRIO-US B-07

Studies & Results


A Phase 1, Open-Label Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

View FDA Study


SABCS 2018

Hoffman J, Chakrabarti J, Wainberg ZA, Plotka A

Evaluation of the effects of talazoparib on QT interval prolongation

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at